Furthermore, identifying structural barriers and prescriber-specific factors associated with the overall likelihood of receiving ERBB2-targeted therapy in more recent time frames, even as guidelines broadly recommend use of these drugs, is crucial to improving quality of breast cancer care. Here, ERBB2 is linked to breast carcinoma.